A significant surge in influenza cases in the UK poses heightened risks for individuals with cystic fibrosis (CF), according to Professor Alex Horsley from The University of Manchester. Recent data reveals a staggering 55% increase in flu cases within a week, with an average of 2,660 patients receiving treatment each day in NHS hospital beds, marking the highest level for this period. In the North West, flu hospitalizations surged by 36.6%, prompting urgent calls for vaccination from health officials.
Patients with CF face unique challenges when confronting influenza. The condition often leads to chronic respiratory infections and persistent cough, typically managed with nebulizer treatments and antibiotics. Nevertheless, influenza can exacerbate lung infections and result in hospital admissions due to severe breathlessness. As a prominent respiratory consultant at Wythenshawe Hospital and Medical Director of the National Institute for Health and Care Research (NIHR) Manchester Clinical Research Facility, Professor Horsley emphasizes the importance of vaccinations and preventive measures during the flu season.
“CF is an inherited condition affecting around 11,000 people in the UK,” Professor Horsley stated. “It primarily impacts the lungs but also affects the pancreas, leading to malnutrition and diabetes, as well as the gut and liver.” He cautions that the winter flu wave can be particularly detrimental for those with CF, urging individuals to take precautions, including timely vaccination.
The CF centre at Wythenshawe Hospital conducts emergency assessments daily to manage acute cases. Professor Horsley noted that ongoing research aims to improve treatment options for CF patients, highlighting a new study titled CF-Tracker. This study, part of a multi-million pound initiative funded by the Cystic Fibrosis Trust, seeks to identify which viruses contribute to severe infections in CF patients and develop new preventive treatments.
Earlier investigations in Manchester indicated that viral infections significantly elevate hospital admissions and the need for intravenous antibiotics among CF patients. The CF-Tracker study, which involves collaboration across the UK, aims to refine the understanding of these viral impacts.
Innovations in CF treatment include the development of CFTR modulators, with Manchester leading the clinical trials for these therapies. Professor Horsley remarked, “Since the introduction of CFTR modulators, many patients experience improved health and reduced lung symptoms.” Despite these advancements, approximately 25% of adults with CF still require intravenous antibiotics annually, with multiple courses leading to serious health concerns and disruptions to daily life.
The impact of flu on individuals with CF is illustrated by the experience of Laura Beattie, who contracted the flu in 2022. She described the ordeal as debilitating, necessitating a visit to the emergency department due to severe breathing difficulties and declining oxygen levels. “I spent the Christmas period on 24/7 oxygen and IV antibiotics, which affected my recovery for months,” Beattie shared.
Her ongoing struggle with viral infections underscores the unpredictable nature of CF exacerbations. “You never know how hard they will hit or how long recovery will take. That uncertainty can be incredibly daunting,” she noted.
As the flu season progresses, health officials continue to stress the importance of vaccination and caution for vulnerable populations, particularly those living with cystic fibrosis. The current flu wave serves as a critical reminder of the need for vigilance and proactive health measures to protect those at higher risk.
